{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:04:38Z","timestamp":1790395478001,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-023-03468-6","type":"journal-article","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T16:04:06Z","timestamp":1674230646000},"page":"1575-1588","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Could immune cells be associated with nephropathy in Fabry disease patients?"],"prefix":"10.1007","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1667-7716","authenticated-orcid":false,"given":"K.","family":"Turkmen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3201-8945","authenticated-orcid":false,"given":"M. A.","family":"Karaselek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8909-8486","authenticated-orcid":false,"given":"S. C.","family":"Celik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8559-2476","authenticated-orcid":false,"given":"H. H.","family":"Esen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9174-0351","authenticated-orcid":false,"given":"H.","family":"Ozer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8751-5490","authenticated-orcid":false,"given":"I.","family":"Baloglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2634-2677","authenticated-orcid":false,"given":"Y.","family":"Ozturk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8860-6132","authenticated-orcid":false,"given":"S. N.","family":"Guner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8247-6405","authenticated-orcid":false,"given":"I.","family":"Reisli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7344-8947","authenticated-orcid":false,"given":"S.","family":"Keles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,20]]},"reference":[{"issue":"1","key":"3468_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.pharmthera.2009.01.003","volume":"122","author":"R Schiffmann","year":"2009","unstructured":"Schiffmann R (2009) Fabry disease. Pharmacol Ther 122(1):65\u201377. https:\/\/doi.org\/10.1016\/j.pharmthera.2009.01.003","journal-title":"Pharmacol Ther"},{"key":"3468_CR2","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/1750-1172-8-116","volume":"8","author":"F Weidemann","year":"2013","unstructured":"Weidemann F, Sanchez-Nino MD, Politei J, Oliveira JP, Wanner C, Warnock DG, Ortiz A (2013) Fibrosis: a key feature of Fabry disease with potential therapeutic implications. Orphanet J Rare Dis 8:116. https:\/\/doi.org\/10.1186\/1750-1172-8-116","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"3468_CR3","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1073\/pnas.0712309105","volume":"105","author":"JM Aerts","year":"2008","unstructured":"Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, van Roomen C, Mirzaian M, Wijburg FA, Linthorst GE, Vedder AC, Rombach SM, Cox-Brinkman J, Somerharju P, Boot RG, Hollak CE, Brady RO, Poorthuis BJ (2008) Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci USA 105(8):2812\u20132817. https:\/\/doi.org\/10.1073\/pnas.0712309105","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"3468_CR4","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.bbadis.2010.05.003","volume":"1802","author":"SM Rombach","year":"2010","unstructured":"Rombach SM, Dekker N, Bouwman MG, Linthorst GE, Zwinderman AH, Wijburg FA, Kuiper S, Vd Bergh Weerman MA, Groener JE, Poorthuis BJ, Hollak CE, Aerts JM (2010) Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease. Biochim Biophys Acta 1802(9):741\u2013748. https:\/\/doi.org\/10.1016\/j.bbadis.2010.05.003","journal-title":"Biochim Biophys Acta"},{"key":"3468_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/8904_2014_371","volume":"22","author":"W Mauhin","year":"2015","unstructured":"Mauhin W, Lidove O, Masat E, Mingozzi F, Mariampillai K, Ziza JM, Benveniste O (2015) Innate and adaptive immune response in Fabry disease. JIMD Rep 22:1\u201310. https:\/\/doi.org\/10.1007\/8904_2014_371","journal-title":"JIMD Rep"},{"key":"3468_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1750-1172-8-47","volume":"8","author":"SM Rombach","year":"2013","unstructured":"Rombach SM, Smid BE, Bouwman MG, Linthorst GE, Dijkgraaf MG, Hollak CE (2013) Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain. Orphanet J Rare Dis 8:47. https:\/\/doi.org\/10.1186\/1750-1172-8-47","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"3468_CR7","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1681\/ASN.2006080816","volume":"18","author":"DP Germain","year":"2007","unstructured":"Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ, Lee P, Loew T, Vedder AC, Abichandani R, Wilcox WR, Guffon N (2007) Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 18(5):1547\u20131557. https:\/\/doi.org\/10.1681\/ASN.2006080816","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"3468_CR8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ymgme.2013.01.018","volume":"108","author":"CS Pereira","year":"2013","unstructured":"Pereira CS, Azevedo O, Maia ML, Dias AF, Sa-Miranda C, Macedo MF (2013) Invariant natural killer T cells are phenotypically and functionally altered in Fabry disease. Mol Genet Metab 108(4):241\u2013248. https:\/\/doi.org\/10.1016\/j.ymgme.2013.01.018","journal-title":"Mol Genet Metab"},{"issue":"1","key":"3468_CR9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ymgme.2012.02.014","volume":"106","author":"MF Macedo","year":"2012","unstructured":"Macedo MF, Quinta R, Pereira CS, Sa Miranda MC (2012) Enzyme replacement therapy partially prevents invariant natural killer T cell deficiency in the Fabry disease mouse model. Mol Genet Metab 106(1):83\u201391. https:\/\/doi.org\/10.1016\/j.ymgme.2012.02.014","journal-title":"Mol Genet Metab"},{"issue":"21","key":"3468_CR10","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1182\/blood-2018-02-835561","volume":"131","author":"JH Rowe","year":"2018","unstructured":"Rowe JH, Delmonte OM, Keles S, Stadinski BD, Dobbs AK, Henderson LA, Yamazaki Y, Allende LM, Bonilla FA, Gonzalez-Granado LI, Celikbilek Celik S, Guner SN, Kapakli H, Yee C, Pai SY, Huseby ES, Reisli I, Regueiro JR, Notarangelo LD (2018) Patients with CD3G mutations reveal a role for human CD3gamma in Treg diversity and suppressive function. Blood 131(21):2335\u20132344. https:\/\/doi.org\/10.1182\/blood-2018-02-835561","journal-title":"Blood"},{"key":"3468_CR11","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.3389\/fimmu.2018.01924","volume":"9","author":"DA Rao","year":"2018","unstructured":"Rao DA (2018) T cells that help B cells in chronically inflamed tissues. Front Immunol 9:1924. https:\/\/doi.org\/10.3389\/fimmu.2018.01924","journal-title":"Front Immunol"},{"key":"3468_CR12","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.2741\/2254","volume":"12","author":"I Sanz","year":"2007","unstructured":"Sanz I, Anolik JH, Looney RJ (2007) B cell depletion therapy in autoimmune diseases. Front Biosci 12:2546\u20132567. https:\/\/doi.org\/10.2741\/2254","journal-title":"Front Biosci"},{"issue":"6","key":"3468_CR13","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1093\/ndt\/gfq306","volume":"26","author":"MD Sanchez-Nino","year":"2011","unstructured":"Sanchez-Nino MD, Sanz AB, Carrasco S, Saleem MA, Mathieson PW, Valdivielso JM, Ruiz-Ortega M, Egido J, Ortiz A (2011) Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. Nephrol Dial Transplant 26(6):1797\u20131802. https:\/\/doi.org\/10.1093\/ndt\/gfq306","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"3468_CR14","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ymgme.2010.03.020","volume":"100","author":"T Togawa","year":"2010","unstructured":"Togawa T, Kodama T, Suzuki T, Sugawara K, Tsukimura T, Ohashi T, Ishige N, Suzuki K, Kitagawa T, Sakuraba H (2010) Plasma globotriaosylsphingosine as a biomarker of Fabry disease. Mol Genet Metab 100(3):257\u2013261. https:\/\/doi.org\/10.1016\/j.ymgme.2010.03.020","journal-title":"Mol Genet Metab"},{"issue":"1\u20132","key":"3468_CR15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ymgme.2016.10.006","volume":"120","author":"A Nowak","year":"2017","unstructured":"Nowak A, Mechtler TP, Desnick RJ, Kasper DC (2017) Plasma LysoGb3: A useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes. Mol Genet Metab 120(1\u20132):57\u201361. https:\/\/doi.org\/10.1016\/j.ymgme.2016.10.006","journal-title":"Mol Genet Metab"},{"issue":"11","key":"3468_CR16","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1007\/s11255-020-02546-3","volume":"52","author":"K Turkmen","year":"2020","unstructured":"Turkmen K, Baloglu I (2020) Fabry disease: where are we now? Int Urol Nephrol 52(11):2113\u20132122. https:\/\/doi.org\/10.1007\/s11255-020-02546-3","journal-title":"Int Urol Nephrol"},{"key":"3468_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13447","author":"M Satoh","year":"2022","unstructured":"Satoh M, Iizuka M, Majima M, Ohwa C, Hattori A, Van Kaer L, Iwabuchi K (2022) Adipose invariant NKT cells interact with CD1d-expressing macrophages to regulate obesity-related inflammation. Immunology. https:\/\/doi.org\/10.1111\/imm.13447","journal-title":"Immunology"},{"key":"3468_CR18","doi-asserted-by":"publisher","first-page":"798155","DOI":"10.3389\/fimmu.2021.798155","volume":"12","author":"MT Palano","year":"2021","unstructured":"Palano MT, Cucchiara M, Gallazzi M, Riccio F, Mortara L, Gensini GF, Spinetti G, Ambrosio G, Bruno A (2021) When a friend becomes your enemy: natural killer cells in atherosclerosis and atherosclerosis-associated risk factors. Front Immunol 12:798155. https:\/\/doi.org\/10.3389\/fimmu.2021.798155","journal-title":"Front Immunol"},{"issue":"1","key":"3468_CR19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12865-020-00378-5","volume":"21","author":"V Mxinwa","year":"2020","unstructured":"Mxinwa V, Dludla PV, Nyambuya TM, Mokgalaboni K, Mazibuko-Mbeje SE, Nkambule BB (2020) Natural killer cell levels in adults living with type 2 diabetes: a systematic review and meta-analysis of clinical studies. BMC Immunol 21(1):51. https:\/\/doi.org\/10.1186\/s12865-020-00378-5","journal-title":"BMC Immunol"},{"issue":"5","key":"3468_CR20","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.humpath.2010.07.023","volume":"42","author":"SE Gibson","year":"2011","unstructured":"Gibson SE, Swerdlow SH, Felgar RE (2011) Natural killer cell subsets and natural killer-like T-cell populations in benign and neoplastic B-cell proliferations vary based on clinicopathologic features. Hum Pathol 42(5):679\u2013687. https:\/\/doi.org\/10.1016\/j.humpath.2010.07.023","journal-title":"Hum Pathol"},{"issue":"3","key":"3468_CR21","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1182\/blood-2007-09-077438","volume":"112","author":"MA Caligiuri","year":"2008","unstructured":"Caligiuri MA (2008) Human natural killer cells. Blood 112(3):461\u2013469. https:\/\/doi.org\/10.1182\/blood-2007-09-077438","journal-title":"Blood"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-023-03468-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-023-03468-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-023-03468-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T15:53:54Z","timestamp":1684166034000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-023-03468-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,20]]},"references-count":21,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["3468"],"URL":"https:\/\/doi.org\/10.1007\/s11255-023-03468-6","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,20]]},"assertion":[{"value":"10 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}